


PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C07F 9/24, A61K 35/28 C07F 9/44	A1	(11) International Publication Number: WO 90/10636 (43) International Publication Date: 20 September 1990 (20.09.90)
(21) International Application Number: PCT/US89/01214 (22) International Filing Date: 22 March 1989 (22.03.89) (30) Priority data: 323,423 14 March 1989 (14.03.89) US (71) Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM [US/US]; 201 West Seventh Street, Austin, TX 78701 (US). (72) Inventor: FARQUHAR, David ; 5134 Rutherglenn, Houston, TX 77096 (US). (74) Agent: HODGINS, Daniel, S.; Arnold, White & Durkee, P.O. Box 4433, Houston, TX 77210 (US).		(81) Designated States: AT, AT (European patent), AU, BE (European patent), BF (OAPI patent), BJ (OAPI patent), BR, CF (OAPI patent), CG (OAPI patent), CH, CH (European patent), CM (OAPI patent), DE, DE (European patent), DK, FI, FR (European patent), GA (OAPI patent), GB, GB (European patent), HU, IT (European patent), JP, KP, LK, LU, LU (European patent), MC, MG, ML (OAPI patent), MR (OAPI patent), MW, NL, NL (European patent), NO, RO, SE, SE (European patent), SN (OAPI patent), SU, TD (OAPI patent), TG (OAPI patent). Published With international search report.

(54) Title: NOVEL ANTITUMOR ALDOPHOSPHAMIDE ANALOGS



(57) Abstract

A compound having structure (I), wherein R is alkyl, aryl, or alkaryl; X is N, NH, NHNH, NHO, ONH, or alkyl; R¹ is hydrogen, alkyl, dialkyl, aryl, chloroalkyl, nitro, amine, benzyloxycarbonyl or t-butoxycarbonyl; and R² is chloroethylamine or bis(chloroethyl)amine. These compounds may be used to eliminate occult leukemic clonogenic cells from bone marrow by contacting the bone marrow with a solution comprising levels of said compound sufficient to eliminate occult leukemic clonogenic cells. Analogously, tumor cells in a host or organ of a host may be eliminated by treatment of the host or host's organ with a compound of this description. Compounds of this description are stable aldophosphamide analogs activatable by the action of an esterase and a subsequent E-2 elimination reaction to form acrolein and a phosphoramidic mustard of formula (II), wherein R is alkyl, aryl, or alkaryl; X is N, NH, NHNH, NHO, ONH, or alkyl; R¹ is hydrogen, alkyl, dialkyl, aryl, chloroalkyl, nitro, amine, benzyloxycarbonyl or t-butoxycarbonyl; and R² is chloroethylamine or bis(chloroethyl)amine. A stable aldophosphamide analog activatable by the action of an esterase and a subsequent spontaneous E-2 elimination reaction to form acrolein and a phosphoramidic mustard, said phosphoramidic mustard having formula (III), wherein R is NH₂, NHCH₃, NHC₂H₅, NHC₃H₇, NHC₄H₉, NHCH₂CH₂Cl, NHC₆H₅, N(CH₃)₂, N(C₂H₅)₂, N(C₃H₇)₂, NCH₃(C₂H₅), NCH₃(C₃H₇), N(CH₂CH₂Cl)₂, NHOH, NHNHCO₂CH₂C₆H₅, NHNHCO₂C(CH₃)₃, OCH₃, OC₂H₅, OC₃H₇, OC₄H₉, OC₆H₅, OC₂C₆H₅, CH₃, C₂H₅, C₃H₇, C₄H₉, CH₂NO₂ or CH₂NH₂; and R¹ is NHCH₂CH₂Cl or N(CH₂CH₂Cl)₂.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MR	Mauritania
BE	Belgium	GA	Gabon	MW	Malawi
BF	Burkina Faso	GB	United Kingdom	NL	Netherlands
BG	Bulgaria	HU	Hungary	NO	Norway
BJ	Benin	IT	Italy	RO	Romania
BR	Brazil	JP	Japan	SD	Sudan
CA	Canada	KP	Democratic People's Republic of Korea	SE	Sweden
CF	Central African Republic	KR	Republic of Korea	SN	Senegal
CG	Congo	LI	Liechtenstein	SU	Soviet Union
CH	Switzerland	LK	Sri Lanka	TD	Chad
CM	Cameroon	LU	Luxembourg	TG	Togo
DE	Germany, Federal Republic of	MC	Monaco	US	United States of America
DK	Denmark				

5

10

NOVEL ANTITUMOR ALDOPHOSPHAMIDE ANALOGS

15

The present invention relates to cyclophosphamide analogs particularly useful for the suppression of tumor cells.

20

Since the demonstration in 1942 that nitrogen mustard was effective at inducing remissions in patients with lymphoma (A. Gilman Amer. J. Surg. 105:574), several thousand structural analogs have been synthesized in an attempt to enhance the selectivity of the parent drug. However, only a few of these compounds have demonstrated sufficient therapeutic superiority to nitrogen mustard in experimental tumor systems to warrant clinical trial. Of these, cyclophosphamide is unquestionably the most important. It has a higher therapeutic index than must other mustard-type alkylating agents and a much broader spectrum of clinical activity. However, the drug is not independently cytotoxic; it requires enzymatic activation in order to exert biologic activity. Although the biotransformation of cyclophosphamide, in vivo, is complex, the following general principles (Figure 1) are

widely accepted (D.L. Hill (1975) A Review of Cyclophosphamide' (Charles C. Thomas, Springfield, Ill. and O.M. Friedman, et al. (1979) Adv. Cancer Chemother. 1:143).

5

As shown in Figure 1, Cyclophosphamide, (1-A), is oxidatively biotransformed, mainly in the liver, by cytochrome P-450 dependent mixed-function oxidases to give 4-hydroxycyclophosphamide, (2-A). This metabolite exists
10 in equilibrium with aldophosphamide (3-A), its open-chain tautomer. Aldophosphamide is labile and undergoes an E2 elimination reaction to generate phosphorodiamidic mustard (5-A) and acrolein (6-A). 4-Hydroxycyclophosphamide and aldophosphamide also undergo further enzymatic oxidation,
15 the former mediated by alcohol dehydrogenases and the latter by aldehyde dehydrogenases or aldehyde oxidases, to give, respectively, 4-ketocyclophosphamide (4-A) and carboxyphosphamide (7-A). Compounds 4-A and 7-A are chemically stable and relatively non-toxic.
20 Phosphorodiamidic mustard (5), a potent alkylating agent, is generally considered to be the ultimate 'active metabolite' of cyclophosphamide.

Although widespread agreement exists on the
25 metabolism of cyclophosphamide, its mechanism of antitumor selectivity has been controversial. However, strong evidence has recently been presented in favor of the Selective Detoxification Hypothesis. The key feature of this hypothesis, first proposed by Sladek ((1973) Cancer
30 Res. 33:1150), and later by Connors, et al. ((1974) Biochemical Pharmacol. 23:114), and Cox, et al. ((1975) Cancer Res. 35:3755), is that the conversion of aldophosphamide to carboxyphosphamide, a biologically inert compound, is less efficient in tumor cells than in
35 most drug-susceptible normal cells (e.g., hematopoietic stem cells) because the latter contain higher levels of

aldehyde dehydrogenases. As a consequence, more
aldophosphamide dissociates to the highly cytotoxic
phosphorodiamidic mustard in tumor cells. It has now been
demonstrated that intracellular levels of aldehyde
5 dehydrogenases are, indeed, an important biologically-
operative determinant of the antitumor selectivity of
cyclophosphamide. Thus, Hilton and Colvin have shown (J.
Hilton, et al. (1984) Proc. Amer. Assoc. Cancer Res.
25:339) that intracellular levels of aldehyde dehydro-
10 genase correlate inversely with cyclophosphamide
sensitivity both in a variety of human and rodent
hematopoietic cell lines, and in human leukemic cells;
high aldehyde dehydrogenase levels were present in drug-
resistant cells. An L1210 resistant cell-line with
15 unusually high aldehyde dehydrogenase activity was
rendered drug-sensitive (J. Hilton (1984) Biochem.
Pharmacol. 33:1867) by pretreating the cells with low
concentrations of disulfiram, an aldehyde dehydrogenase
inhibitor. Equally significant, 4-hydroxycyclophosphamide
20 was extensively converted to carboxyphosphamide, an
inactive metabolite, when incubated with extracts from the
drug resistant L1210 cell-line (J. Hilton (1984) Cancer
Res. 44:5156). By contrast, negligible levels of carboxy-
phosphamide, were formed when 4-hydroxycyclophosphamide
25 was incubated, under the same conditions, with extracts
from the drug-sensitive cell line. The author concluded
(J. Hilton (1984) Cancer Res. 4: 5156): '4-Hydroxy-
cyclophosphamide and/or aldophosphamide is the form in
which cyclophosphamide reaches these tumor cells in mice
30 and that intracellular aldehyde dehydrogenase activity is
an important determinant of cyclophosphamide sensitivity
in these cell lines'.

Sladek has reported (N.E. Sladek, et al. (1985)
35 Cancer Res. 45:1549) that three known (and one suspected)
inhibitors of aldehyde dehydrogenase activity [disulfiram,

diethyl dithiocarbamate, cyanamide, and (ethylphenyl (2-formylethyl) phosphinate)] potentiate the cytotoxicity of 4-hydroperoxycyclophosphamide and ASTA Z 7557 (Conference proceedings published in: (1984) Investigational New
5 Drugs 2:1-259), (both latent precursors of 4-hydroxycyclophosphamide) when incubated against cyclophosphamide-resistant L1210 and P-388 cell-lines. Significantly, no potentiation was observed with phosphordiamidic mustard, the presumed active metabolite
10 of cyclophosphamide. In further studies, Sladek has shown (F.R. Kohn, et al. (1984) Proc. Amer. Assoc. Cancer Res. 25:289); (F.R. Kohn, et al. (In press) Biochem. Pharmacol) that aldehyde dehydrogenase activity is an important determinant of the differential sensitivities of murine
15 pluripotent hematopoietic stem cells and granulocyte-macrophage myeloid pregenitor cells to various activated cyclophosphamide analogs, including 4-hydroperoxycyclophosphamide and ASTA Z 7557. This finding likely accounts for the relative sparing effect of
20 cyclophosphamide on myeloid stem cells.

Friedman, et al. (O.M. Friedman (1979) Adv. Cancer Chemother. 1:143) and, more recently, Zon (G. Zon (1982) Progress in Medicinal Chemistry 19:205) have strongly
25 emphasized the need for further investigations in the mechanism of selectivity of cyclophosphamide and its analogs. The present application relates to new information that is critically relevant to this question. An important advantage of the present invention is the
30 incorporation of structural and mechanistic features that contribute to the selectivity of cyclophosphamide into other antitumor drugs to enhance their therapeutic efficacy.

35 Advances in the treatment of acute myeloid leukemia in adults has generally been due to the introduction of

new cytostatic drugs. The most important of these have been arabinosyl cytosine (Ara-C), the anthracyclines, and m-AMSA. Different combinations of these drugs give remission rates of about 60-70% (R.P. Gale (1977) Lancet 1:497); (J.F. Holland, et al. (1976) Arch. Intern. Med. 136:1377); and (K.B. McCredie, et al. (1981) Proc. A.S.C.O. and AACR 22:479); however, the median duration of complete remission is less than 18 months, with a "cured" fraction of less than 20%.

10 In contrast, long-term relapse-free survival can be achieved in about 50% of AML-patients after high-dose chemotherapy and total body irradiation followed by allogeneic bone marrow transplantation in first remission 15 (R.A. Clift, et al. (1985) Blood 66(5):887 (Abstract); (A. Fefer, et al. (1983) Blood 57:421); and, (K.G. Blume, et al. (1980) N. Engl. J. Med. 302:1041). Similar results have been obtained in patients with relapsing or refractory acute leukemia who receive bone marrow 20 transplantation from an identical twin, after supralethal chemoradiotherapy (R.L. Powles, et al. (1980) Lancet 1:1047). Unfortunately, only about 25% of all patients have an HLA-compatible sibling available or bone marrow donation. The patient's own bone marrow can, however, be 25 harvested in complete remission, cryopreserved, and used as a source of syngeneic hematopoietic stem cells for graftment purpose. This procedure allows a transplantation conditioning regimen with high-dose chemo- or chemoradiotherapy aimed at eradicating dormant leukemic 30 cells in sanctuary sites like testicles, ovaries and the central nervous system. The problem that prevents more widespread use of cryopreserved autologous bone marrow is the presence of occult clonogenic leukemic cells in remission bone marrow. Thus, results obtained with 35 autologous bone marrow transplantation for AML in first remission do not differ significantly from that obtained

with chemotherapy alone (A. Fefer, et al. (1983) Blood 57:421). Ten evaluable patients were treated in second remission, with high-dose chemotherapy followed by autologous marrow transplant. Of those, one was alive in remission at 30 months, seven relapsed (range 1-8 months) and two died early. The feasibility of using in vitro immunologic or pharmacologic treatment of remission bone marrow to eliminate occult leukemic clonogenic cells capable of causing relapse of the disease has been convincingly proven in animal model systems (P. Stewart, et al. (1985) Exp. Hematol. 13:267); (S.J. Sharkis, et al. (1980) Blood 55:521); (H. Coizer, et al. (1982) Proc AACR 23:194); (M. Korbling, et al. (1982) Br. J. Haematol 52:89); and, (S. Thierfelder, et al. (1977) Eur J. Cancer 15:1357). Early data for in vitro treatment ("purging") of human remission bone marrow indicate that methodology can be designed that allows successful engraftment of the patients with in vitro manipulated marrow. The available methods that have been used so far include:

- (a) treatment of bone marrow with antibodies plus complement;
- (b) treatment with antibodies linked to a toxin e.g. ricin;
- (c) pharmacologic treatment with an in vitro active drug.

The major weakness with the immunological "purging" methods is the lack of proven specific acute leukemia antigens that would distinguish leukemic cells from normal hemopoietic stem cells. Another technical problem is the limited availability of large quantities of monoclonal antibodies for in vitro treatment of large volumes of bone marrow.

For pharmacologic purging, the ideal drug(s) should preferably selectively kill leukemic stem cells while leaving the normal stem cells intact to allow for hemopoietic reconstitution. Obviously, such techniques
5 alleviate the problem of finding specific anti-leukemia antibodies. Another advantage is that drug can easily be manufactured in large quantities under standardized conditions. One drug that has a possible selective action against leukemic versus normal cells is cyclophosphamide.
10 Its in vitro active congener 4-hydroperoxycyclophosphamide, has recently received much attention for purging purposes both in murine models (P. Stewart, et al. (1985) Exp. Hematol. 13:267); (S.J. Sharkis, et al. (1980) Blood 55:521); (H. Coizer, et al. (1982) Proc AACR 23:194); (M. Korbling, et al. (1982) Br. J. Haematol. 52:89); (S. Thierfelder, et al. (1977) Eur. J. Cancer 15:1357); (E.S. Vitetta, et al. (1982) Immunol. Rev. 62:160) and in a clinical setting (A. Hagenbeck and A.C.M. Martens (1981) Exp. Hematol. 10 (Suppl. 11):14);
15 (H. Kaizer, et al. (1981) Exp. Haematol. 9 (Suppl. 372):190) and, (L. Douay, et al. (1982) Exp. Hematol. 10 (Suppl. 12):113.


The major shortcomings of 4-hydroperoxycyclophosphamide (4-HC) is that it has a relatively short half-life in vitro (less than 2 hrs) and that its toxic action decreases with increasing cell concentration. Furthermore, the supply of doses is limited. To circumvent these short-comings, a new series
25 of in vitro active oxazaphosphorines is a subject of the present invention. The present application relates to investigating the in vitro activity of these compounds in human myeloid leukemic cell lines that have been developed and recently characterized, both the parent lines and
30 sublines resistant to two of the other major anti-leukemic drugs, adriamycin and m-AMSA in comparison to their action

on normal committed myeloid stem cells and pluripotent hemopoietic stem cells. A long-term goal of the present invention enables the techniques that may be applied in clinical setting for autologous bone marrow
5 transplantation.

Among the objectives of the present invention are:

- 10 (1) to develop a model for in vitro treatment of human bone marrow, obtained from patients with acute myeloid leukemia in complete remission, with a novel series of in vitro active oxazaphosphorines,
- 15 (2) to determine the optimal condition under which maximum leukemic clonogenic cell kill can be achieved with sparing of hemopoietic regenerative capacity,
- 20 (3) to examine possible quantitative differences between myeloid leukemic and normal hemopoietic stem cells in the make-up of activating and degrading enzymatic machinery responsible for the resulting cytotoxicity, and
25
- (4) to explore different avenues of manipulating cellular aldehyde dehydrogenase activity, thereby augmenting differences in cytotoxicity between normal and leukemic clonogenic stem cells.
30


In one view, the present invention involves a compound having the structure:




- 10 wherein R is CH₃, C₂H₅, C₃H₇, t-C₄H₉ or C₆H₅; R¹ is NH₂,
 NHCH₃, NHC₂H₅, NHC₃H₇, NHC₄H₉, NHCH₂CH₂Cl, NHC₆H₅,
 N(CH₃)₂, N(C₂H₅)₂, N(C₃H₇)₂, NCH₃(C₂H₅), NCH₃(C₃H₇),
 N(CH₂CH₂Cl)₂, NHOH, NHNHCO₂CH₂C₆H₅, NHNHCO₂C(CH₃)₃, OCH₃,
 15 OC₂H₅, OC₃H₇, OC₄H₉, OC₆H₅, OCH₂C₆H₅, CH₃, C₂H₅, C₃H₇,
 C₄H₉, CH₂NO₂ or CH₂N₂ and R² is NHCH₂CH₂Cl or
 N(CH₂CH₂Cl)₂.

Any one of these compounds may be used to eliminate occult
 20 leukemic clonogenic cells from bone marrow by contacting
 the bone marrow with a solution comprising sufficient
 levels of said compound. Analogously, tumor cells in a
 host or organ of a host may be eliminated by treatment of
 the host or host's organ with a compound of this
 25 description.

Compounds of this description are stable
 aldophosphamide analogs activatable by the action of an
 esterase and a subsequent elimination reaction to form
 30 acrolein and a phosphoramidic mustard of the formula:




or



10 wherein R^1 is NH_2 , NHCH_3 , NHC_2H_5 , NCH_3H_7 , NHC_4H_9 ,
 $\text{NHCH}_2\text{CH}_2\text{Cl}$, NHC_6H_5 , $\text{N}(\text{CH}_3)_2$, $\text{N}(\text{C}_2\text{H}_5)_2$, $\text{N}(\text{C}_3\text{H}_7)_2$,
 $\text{NCH}_3(\text{C}_2\text{H}_5)$, $\text{NCH}_3(\text{C}_3\text{H}_7)$, $\text{N}(\text{CH}_2\text{CH}_2\text{Cl})_2$, NHOH ,
 $\text{NHNHCO}_2\text{CH}_2\text{C}_6\text{H}_5$, $\text{NHNHCO}_2\text{C}(\text{CH}_3)_3$, OCH_3 , OC_2H_5 , OC_3H_7 , OC_4H_9 ,
 OC_6H_5 , $\text{OCH}_2\text{C}_6\text{H}_5$, CH_3 , C_2H_5 , C_3H_7 , C_4H_9 , CH_2NO_2 or CH_2NH_2 .

15

The present invention may be further described as including a compound having the structure



25 wherein:

R is alkyl, aryl, or alkaryl;

X is N, NH, NHNH, NHO, ONH, alkyl;

30 R^1 is hydrogen, alkyl, dialkyl, aryl, chloroalkyl, nitro,
 amine, benzyloxycarbonyl or t-butoxycarbonyl; and


-11-

R^2 is chloroethylamine or bis(chloroethyl)amine.

Additionally included in the present invention is a compound having the structure:

5

10



wherein:

R is CH_3 , C_2H_5 , C_3H_7 , $t\text{-C}_4\text{H}_9$ or C_6H_5 ;

15


R^1 is NH_2 , NHCH_3 , NHC_2H_5 , NHC_3H_7 , NHC_4H_9 , $\text{NHCH}_2\text{CH}_2\text{Cl}$, NHC_6H_5 , $\text{N}(\text{CH}_3)_2$, $\text{N}(\text{C}_2\text{H}_5)_2$, $\text{N}(\text{C}_3\text{H}_7)_2$, $\text{NCH}_3(\text{C}_2\text{H}_5)$, $\text{NCH}_3(\text{C}_3\text{H}_7)$, $\text{N}(\text{CH}_2\text{CH}_2\text{Cl})_2$, NHOH , $\text{NHNHCO}_2\text{CH}_2\text{C}_6\text{H}_5$, $\text{NHNHCO}_2\text{C}(\text{CH}_3)_3$, OCH_3 , OC_2H_5 , OC_3H_7 , OC_4H_9 , OC_6H_5 , $\text{OC}_2\text{C}_6\text{H}_5$, CH_3 , C_2H_5 , C_3H_7 , C_4H_9 , CH_2NO_2 or CH_2NH_2 ; and

20

R^2 is $\text{NHCH}_2\text{CH}_2\text{Cl}$ or $\text{N}(\text{CH}_2\text{CH}_2\text{Cl})_2$.

In broader view, the present invention describes stable aldophosphamide analogs activatable by the action of an esterase and a subsequent spontaneous E-2 elimination reaction to form acrolein and a phosphoramidic mustard, said phosphoramidic mustard having the formula

30



wherein:


R is NH_2 , NHCH_3 , NHC_2H_5 , NHC_3H_7 , NHC_4H_9 , $\text{NHCH}_2\text{CH}_2\text{Cl}$,
 NHC_6H_5 , $\text{N}(\text{CH}_3)_2$, $\text{N}(\text{C}_2\text{H}_5)_2$, $\text{N}(\text{C}_3\text{H}_7)_2$, $\text{NCH}_3(\text{C}_2\text{H}_5)$,
 5 $\text{NCH}_3(\text{C}_3\text{H}_7)$, $\text{N}(\text{CH}_2\text{CH}_2\text{Cl})_2$, NHOH , $\text{NHNHCO}_2\text{CH}_2\text{C}_6\text{H}_5$,
 $\text{NHNHCO}_2\text{C}(\text{CH}_3)_3$, OCH_3 , OC_2H_5 , OC_3H_7 , OC_4H_9 , OC_6H_5 ,
 $\text{OC}_2\text{C}_6\text{H}_5$, CH_3 , C_2H_5 , C_3H_7 , C_4H_9 , CH_2NO_2 or CH_2NH_2 ; and

R^1 is $\text{NHCH}_2\text{CH}_2\text{Cl}$ or $\text{N}(\text{CH}_2\text{CH}_2\text{Cl})_2$.

10

Additionally, the present invention involves a compound having the structure:

15



20 wherein:


R is CH_3 , C_2H_5 , C_3H_7 , $\text{C}(\text{CH}_3)_2$ or C_6H_5 ;

R^1 is NH_2 , NHCH_3 , NHCH_2CH_3 , $\text{NHCH}_2\text{CH}_2\text{Cl}$, $\text{N}(\text{CH}_3)_2$,
 25 $\text{N}(\text{CH}_2\text{CH}_3)_2$, $\text{N}(\text{CH}_2\text{CH}_2\text{Cl})_2$, $\text{NHCH}_2\text{CH}_2\text{CH}_2\text{CH}_3$, $\text{NCH}_3(\text{C}_2\text{H}_5)$,
 $\text{NCH}_3(\text{C}_3\text{H}_7)$, NHC_6H_5 , NHOH , $\text{NHNHCO}_2\text{CH}_2\text{C}_6\text{H}_5$,
 $\text{NHNHCO}_2\text{C}(\text{CH}_3)_3$, OCH_3 , OCH_2CH_3 , OC_3H_7 , OC_4H_9 , OC_6H_5 ,
 $\text{OCH}_2\text{C}_6\text{H}_5$, $\text{ONHCO}_2\text{C}(\text{CH}_3)_3$, $\text{OCH}_2\text{CH}_2\text{CH}(\text{OAc})_2$,
 30 $\text{OP}(\text{O})\text{N}(\text{CH}_2\text{CH}_2\text{Cl})_2$, CH_3 , CH_2CH_3 , $\text{CH}_2\text{CH}_2\text{CH}_3$,
 $\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$, CH_2NO_2 , or CH_2NH_2 ; and

R^2 is $\text{N}(\text{CH}_2\text{CH}_2\text{Cl})_2$ or $\text{NHCH}_2\text{CH}_2\text{Cl}$.

Compounds of the present invention include those
 35 having the structure:

-13-



wherein:


10 R is CH₃, C₂H₅, C₃H₇, C(CH₃)₂ or C₆H₅;

R¹ is a cytotoxic glycoside ; and

R² is N(CH₂CH₂Cl)₂ or NHCH₂CH₂Cl.

15 In more particularity, the R¹ cytotoxic glycoside is N-(3')-Doxorubicin or N-(3')-Daunorubicin. Such adriamycin derivatives should be selectively activated in tumor cells and be effective chemotherapeutic agents.

20 Another chemotherapeutic compound of the present invention is one having the structure:



wherein:

30

R is CH₃, C₂H₅, C₃H₇, C(CH₃)₂ or C₆H₅;

R^1 is NH_2 ; and

R^2 is a nucleoside.

Preferred R^2 nucleosides are 2',3'-dideoxyuridine-5'yl
5 and 5-methyl-2',3'- dideoxyuridine.

Figure 1 schematically shows the generally accepted pathway for cyclophosphamide metabolism.

10 Figure 2 schematically shows the activation pathway for compounds of the present invention.

Figure 3 schematically shows a synthetic pathway for compounds of the present invention.

15

Figure 4 further schematically shows a synthetic pathway for compounds of the present invention.

Figure 5 schematically shows a synthetic scheme
20 resulting in a compound of the present invention.

Figure 6 schematically shows the structures of doxorubicin and daunomycin.

25 Figure 7 shows the proposed activation mechanism of compounds of the present invention.

Figure 8 shows the anticipated mechanism of action of compounds of the present invention.


30

Objectives of this invention include the synthesis, biological evaluation and therapeutic use of a series of analogs of aldophosphamide, one of the major primary metabolites of cyclophosphamide. The analogs are designed
35 to elucidate the structural correlates of antitumor activity for this general class of compounds, particularly

the contribution of intermediate '4-hydroxy' cyclic structures to drug selectivity. A further major goal is to extend these key structural features to other cytotoxic agents in an attempt to enhance their therapeutic efficacy.

Novel aspects of studies with aldophosphamide analogs have shown that the analogs, unlike aldophosphamide, are chemically stable under neutral aqueous conditions. However, in the presence of carboxylate hydrolases (esterases), they will convert rapidly to unstable intermediates. Some of these intermediates can form cyclic derivatives, and exhibit chemical and biologic properties similar to those of aldophosphamide; other analogs which cannot cyclize, may exhibit substantially different properties. Correlation of the biologic properties of these compounds with their physicochemical characteristics should help clarify the structural correlates of antitumor selectivity.

Many compounds of the present invention are comprised in the following list. These new compounds have the following general structure:



B

Where R, R¹ and R² are shown in Table 1 below for fifty-three model compounds.

TABLE 1

5	Compound No.	R	R^1	R^2
	B-1)	CH_3	NH_2	$N(CH_2CH_2Cl)_2$
	B-2)	CH_3	$NHCH_3$	$N(CH_2CH_2Cl)_2$
	B-3)	CH_3	$NHCH_2CH_3$	$N(CH_2CH_2Cl)_2$
	B-4)	CH_3	$NHCH_2CH_2Cl$	$N(CH_2CH_2Cl)_2$
10	B-5)	CH_3	$N(CH_3)_2$	$N(CH_2CH_2Cl)_2$
	B-6)	CH_3	$N(CH_2CH_3)_2$	$N(CH_2CH_2Cl)_2$
	B-7)	CH_3	$N(CH_2CH_2Cl)_2$	$N(CH_2CH_2Cl)_2$
	B-8)	CH_3	OCH_3	$N(CH_2CH_2Cl)_2$
	B-9)	CH_3	OCH_2CH_3	$N(CH_2CH_2Cl)_2$
15	B-10)	CH_3	CH_3	$N(CH_2CH_2Cl)_2$
	B-11)	CH_3	CH_2CH_3	$N(CH_2CH_2Cl)_2$
	B-12)	CH_3	$NHCH_2CH_2Cl$	$NHCH_2CH_2Cl$
	B-13)	C_2H_5	NH_2	$N(CH_2CH_2Cl)_2$
	B-14)	C_2H_5	$NHCH_3$	$N(CH_2CH_2Cl)_2$
20	B-15)	C_2H_5	$NHCH_2CH_2Cl$	$NHCH_2CH_2Cl$
	B-16)	C_2H_5	$NHCH_2CH_2Cl$	$N(CH_2CH_2Cl)_2$
	B-17)	C_2H_5	$N(CH_2CH_2Cl)_2$	$N(CH_2CH_2Cl)_2$
	B-18)	CH_3	$NHCH_2CH_2CH_3$	$N(CH_2CH_2Cl)_2$
	B-19)	CH_3	$NHCH_2CH_2CH_2CH_3$	$N(CH_2CH_2Cl)_2$
25	B-20)	CH_3	$NCH_3(C_2H_5)$	$N(CH_2CH_2Cl)_2$
	B-21)	CH_3	$NCH_3(C_3H_7)$	$N(CH_2CH_2Cl)_2$
	B-22)	CH_3	NHC_6H_5	$N(CH_2CH_2Cl)_2$
	B-23)	CH_3	$NHOH$	$N(CH_2CH_2Cl)_2$
	B-24)	CH_3	$NHNHCO_2CH_2C_6H_5$	$N(CH_2CH_2Cl)_2$
30	B-25)	CH_3	$NHNHCO_2C(CH_3)_3$	$N(CH_2CH_2Cl)_2$
	B-26)	CH_3	OC_3H_7	$N(CH_2CH_2Cl)_2$
	B-27)	CH_3	OC_4H_9	$N(CH_2CH_2Cl)_2$
	B-28)	CH_3	OC_6H_5	$N(CH_2CH_2Cl)_2$
	B-29)	CH_3	$OCH_2C_6H_5$	$N(CH_2CH_2Cl)_2$
35	B-30)	CH_3	$ONHCO_2C(CH_3)_3$	$N(CH_2CH_2Cl)_2$
	B-31)	CH_3	$OCH_2CH_2CH(OAc)_2$	$N(CH_2CH_2Cl)_2$

	B-32	CH ₃	OP(O)N(CH ₂ CH ₂ Cl) ₂	N(CH ₂ CH ₂ Cl) ₂
	B-33	CH ₃	CH ₂ CH ₂ CH ₃	N(CH ₂ CH ₂ Cl) ₂
	B-34	CH ₃	CH ₂ CH ₂ CH ₂ CH ₃	N(CH ₂ CH ₂ Cl) ₂
	B-35	CH ₃	CH ₂ NO ₂	N(CH ₂ CH ₂ Cl) ₂
5	B-36	CH ₃	CH ₂ NH ₂	N(CH ₂ CH ₂ Cl) ₂
	B-37	CH ₃	CH ₂ CH ₂ CH ₃	N(CH ₂ CH ₂ Cl) ₂
	B-38	CH ₃	CH ₂ CH ₂ CH ₂ CH ₃	N(CH ₂ CH ₂ Cl) ₂
	B-39	C ₃ H ₇	NH ₂	N(CH ₂ CH ₂ Cl) ₂
	B-40	C ₃ H ₇	NHCH ₃	N(CH ₂ CH ₂ Cl) ₂
10	B-41	C ₃ H ₇	NHCH ₂ CH ₂ Cl	NHCH ₂ CH ₂ Cl
	B-42	C ₃ H ₇	NHCH ₂ CH ₂ Cl	N(CH ₂ CH ₂ Cl) ₂
	B-43	C ₃ H ₇	N(CH ₂ CH ₂ Cl) ₂	N(CH ₂ CH ₂ Cl) ₂
	B-44	C(CH ₃) ₃	NH ₂	N(CH ₂ CH ₂ Cl) ₂
	B-45	C(CH ₃) ₃	NHCH ₃	N(CH ₂ CH ₂ Cl) ₂
15	B-46	C(CH ₃) ₃	NHCH ₂ CH ₂ Cl	NHCH ₂ CH ₂ Cl
	B-47	C(CH ₃) ₃	NHCH ₂ CH ₂ Cl	N(CH ₂ CH ₂ Cl) ₂
	B-48	C(CH ₃) ₃	N(CH ₂ CH ₂ Cl) ₂	N(CH ₂ CH ₂ Cl) ₂
	B-49	C ₆ H ₅	NH ₂	N(CH ₂ CH ₂ Cl) ₂
	B-50	C ₆ H ₅	NHCH ₃	N(CH ₂ CH ₂ Cl) ₂
20	B-51	C ₆ H ₅	NHCH ₂ CH ₂ Cl	NHCH ₂ CH ₂ Cl
	B-52	C ₆ H ₅	NHCH ₂ CH ₂ Cl	N(CH ₂ CH ₂ Cl) ₂
	B-53	C ₆ H ₅	N(CH ₂ CH ₂ Cl) ₂	N(CH ₂ CH ₂ Cl) ₂

The mechanism of activation of these compounds can be
 25 illustrated with respect to compound B-1. In the presence
 of carboxylate esterase, one of the carboxylate ester
 bonds of compound B-1 (1-C in Figure 2) is cleaved (Figure
 2) to generate the corresponding hemiacetal, 2-C. This
 compound then undergoes cleavage of the second ester group
 30 to give the hydrate, 3-C, which exists in equilibrium with
 the free aldehyde, 4-C. The hemiacetal, 2-C, may also
 spontaneously eliminate acetic acid to give the aldehyde,
 4-C, directly. Once generated, the aldehyde, 4-C, will
 rapidly tautomerize to form an equilibrium mixture with
 35 4-hydroxycyclophosphamide, 5-C. However, since aldehyde,
 4-C, is inherently chemically labile, the tautomeric

-18-

mixture will gradually dissociate by an E2 elimination reaction to generate the potentially cytotoxic phosphoramidate mustard, 6-C, and acrolein, 7-C.

5 The biologic properties of the new latent
aldophosphamides are dependent on the steric and
electronic character of the R, R¹, and R² substituents,
since these parameters influence (1) the rate at which the
compounds are bioactivated (2) the position of equilibrium
10 of the aldophosphamide/4-hydroxycyclophosphamide
tautomeric mixtures (3) the susceptibilities of the
aldophosphamides to E2 elimination and (4) the chemical
reactivities of the ultimate alkylating phosphoramidate
mustards. An understanding of the contribution of these
15 substituents to the antitumor and immunosuppressive
properties of this novel class of compounds is vital to
the application of the above concepts in the design of
further new organophosphate therapeutic agents.

20 These new compounds have many potential application
in medicine, particularly clinical oncology. One
important application, autologous bone marrow
transplantation, has already been mentioned. Another is
the regional perfusion of tumors. Yet another is the
25 local treatment of organ (e.g., pleural) tumor effusions.
The new agents are also well suited to in vitro tumor
sensitivity determination prior to systemic drug
administration. However, long range goals relating to the
present invention are to exploit the above concepts to
30 develop new structural types of antitumor and
immunosuppressive agents that exert their activities by
molecular mechanisms fundamentally different from that of
cyclophosphamide. The potential to develop such agents is
now at hand.

The present invention comprises synthesis and uses of stable precursors of aldophosphamide that convert rapidly to the free aldehyde under physiologic conditions. Despite extensive endeavor, this has never been accomplished before. An excellent review of this entire area of investigation has been provided by Zon et al. (G. Zon (1982) Progress in Medicinal Chemistry 19:205). Currently, all preactivated analogs of cyclophosphamide that are used as experimental tools or that possess clinical promise (e.g. 4-hydroxycyclophosphamide, 4-hydroperoxycyclophosphamide, ASTA Z 7557), are cyclic structures that give rise to the ultimate active metabolites through the intermediacy of 4-hydroxycyclophosphamide. Major stability and formulation problems exist with many of these compounds. The opportunity to conduct mechanistic and therapeutic studies on analogs that initially give rise to aldophosphamide or to closely related structures, some of which cannot cyclize, has never before existed. Stable, open-chain aldophosphamide precursors that facilely generate the corresponding free aldehydes under physiologic conditions are inherently chemically and biologically interesting. Clearly, they are as useful, both as experimental tools and as clinical agents, as the ASTA series of compounds prepared in Germany that are the focus of intense experimental and clinical investigation and was the subject of a major international conference (Conference proceedings published (1984) Investigational New Drugs 2:1-259).

30


An unlimited number of stable, chemically-diverse, aldophosphamide analogs can readily be prepared using the approach described herein. Since the activating esterases are ubiquitous in tissue (K. Krisch (1971) The Enzymes 5:44, Academic Press), the compounds will facilely convert to the corresponding free aldehydes in all biological

35

media, including tissue culture. The approach, therefore, is extremely broad in scope. By contrast, only a few 'preactivated' cyclic analogs are known. These latter compounds are synthesized from cyclophosphamide by a
5 stepwise sequence in low overall yield. They are difficult to purify and are inherently chemically labile. Moreover, their limited availability and high cost are prohibitive of their widespread clinical use. It is not surprising that few such compounds have been reported, and
10 that systemic structure/activity relationship studies with these compounds have never been undertaken. In addition cellular pharmacology studies with cyclic preactivated analogs are exceedingly difficult because radiolabeled formulations are not readily accessible. By comparison,
15 none of these problems exist with the aldophosphamide analogs of the present invention.

The requirement for cyclic structural geometry places severe constraints on the types of analogs that can be
20 prepared, severely limiting structure activity studies. These considerations are far from academic because the mechanistic principles that contribute to the antitumor selectivity of cyclophosphamide should be extendable, in principle, to a wide variety of other structures but be
25 unrealizable, in practice, because of the severe molecular constraints imposed by the ring configuration. Using the new approach of the present invention, virtually any conceivable analog of the general formulae, C, described below, can now be readily prepared (for structure-activity
30 relationship studies, if necessary) with the important added assurance that it will almost certainly be activated in vivo. This approach cannot even be considered using cyclic structures.

-21-

C

Wherein Y is P or S; X is O, S or NZ (Z is H or alkyl); one or both of R and R¹ is (are) cytotoxins (when only one is a cytotoxin, the other is H, CH₂Z, NZ₂,) OZ or SZ (where Z is H or alkyl)). Typical cytotoxins include
 15 adriamycin, nucleoside derivatives and phosphoramidic mustards.

One major application of the strategy, and one that constitutes an important object of the invention described
 20 herein, is to extend the above principles to antitumor nucleosides in order to enhance their therapeutic efficacy.

A series of cyclophosphamide analogs has been
 25 synthesized and evaluated to elucidate their mechanism of oncostatic selectivity for cancer cells. The ED₅₀ values of these compounds against L1210 lymphatic leukemia cells have been determined. Some of these analogs have been found to have a greater therapeutic efficacy than ASTA Z
 30 7557 with an in vitro assay.

Cyclophosphamide(1-A) shown in Figure 1, is a widely used antitumor drug. Its metabolism has been well known (Figure 1). It is first activated in liver by "mixed-
 35 function" oxidases to give the intermediate 4-hydroxy-cyclophosphamide(2-A), which undergoes a rapidly equilibrium with its open-chain tautomer aldophosphamide(3-A). The aldophosphamide degrades


spontaneously to give 3-carbon-unit acrolein(4-A) and the ultimate cytotoxic moiety, phosphoramidate mustard(5-A). During the biotransformation process. Some other reactions also occur. 4-Hydroxycyclophosphamide is reduced by
5 dehydrogenases to give 4-ketocyclophosphamide(6-A), which is biologically inactive. Aldophosphamide is reduced by either aldehyde dehydrogenases or aldehyde oxidases or both to give carboxyphosphamide(7-A), which is non-toxic.

10 Although this pathway of cyclophosphamide metabolism has been generally accepted, less is known with certainty about the mechanisms of the cytotoxic selectivity of the cyclophosphamide. It has been proposed, as mentioned earlier herein, that the conversion of aldophosphamide to
15 carboxyphosphamide, a biologically inactive metabolite, is less efficient in tumor cells than in normal cells because the tumor cells contain less aldehyde dehydrogenases than the normal cells. As a consequence, more of the highly cytotoxic phosphoramidate mustard, which is considered to be
20 the 'ultimate active metabolite', is formed from the aldophosphamide in the tumor cells.

The present invention concerns a series of compounds which are chemically stable, but are converted to aldehyde
25 compounds rapidly in the presence of carboxylate esterases. Some of these compounds can cyclize but some cannot.

Certain compounds of the present invention may be
30 expressed as having the structure

-23-



10 wherein R is alkyl, aryl, or alkaryl; X is N, NH, NHH, NHO, ONH, or alkyl; R¹ is hydrogen, alkyl, dialkyl, aryl, chloroalkyl, nitro, amino, benzyloxycarbonyl or t-butoxycarbonyl; R² is chloroethylamine or bis(chloroethyl)amine.

15

Occult leukemic clonogenic cells may be eliminated from bone marrow by contacting the bone marrow with a solution comprising a sufficient level of one or more of the above compounds. Tumor cells from a host or an organ of a host may be likewise eliminated. A sufficient level of one or more of the above compounds is generally between about 5 mg/ml and about 30 mg/ml.

25 The compounds of the present invention represent new and effective tools for selectively eliminating occult leukemic clonogenic cells from bone marrow.

The following examples are presented to describe preferred embodiments and utilities of the present invention and are not meant to limit the present invention unless otherwise stated in the claims appended hereto.

EXAMPLE 1

SYNTHESIS OF CYCLOPHOSPHAMIDE ANALOGS

35 The synthetic pathways are shown in Figure 3. Acrolein, 8-D, was reacted with benzyl alcohol, 9-D, in

the presence of monochloroacetic acid, acetic acid and sodium hydroxide as a catalyst, to give compound 10-D (Yamaguchi, et al. (1971) Chem. Abs. 74:523). Compound 10-D and acetic anhydride reacted rapidly to give compound 11-D in the presence of boron trifluoride/diethyl etherate (Edmund L. Niedzielski (1966) Chem. Abs. 65:6980). Compound 11-D was hydrogenolized over palladium-on-charcoal to give compound 12-D, which was crystallized with cooling. 1 equivalent of compound 12-D and triethylamine were added to 3 equivalents of phosphorus oxychloride (Takamizawa, et al., J. Med. Chem. 18 4.376) then 1 equivalent of bis(2-chloroethyl)amine hydrochloride and triethylamine were added. When the reaction was completed, the reaction mixture was washed with water and phosphate buffer, subjected to column chromatography, and eluted with ethylacetate and hexane. Compound 14-D was obtained as an oil. The amine [NH_3 , $\text{HCl NH}_2\text{CH}_3$, $\text{HCl NH}_2\text{CH}_2\text{CH}_3$, $\text{HCl N}(\text{CH}_3)_2$, or $\text{NH}(\text{CH}_2\text{CH}_3)_2$] was reacted with 14-D to give compound 15-D, 16-D, 17-D, 18-D or 19-D respectively (Figure 3).

The acrolein (99%), benzyl alcohol (99%), acetic anhydride (A.C.S. reagent), phosphorous oxychloride (99%), bis(2-chloroethyl)amine hydrochloride (98%), ethylamine (anhydrous, 99%), dimethylamine hydrochloride (97%), diethyl amine (98%), methanol (99.9+%), ethanol (anhydrous), and 2-chloroethylamine hydrochloride (98%), were all purchased from Aldrich Chemical Co. The ammonia (anhydrous) and monomethylamine (gas) were from Matheson.

3-Benzoyloxypropionaldehyde (10-D) synthesis. 2.85 g of sodium hydroxide and 6.72 g of monochloroacetic acid were dissolved in water separately and then mixed. The solution was then mixed with 123 ml of benzyl alcohol and added to 100ml of acrolein in a 500ml flask dropwise. 30ml of acetic acid was added to the flask and heated 80

hours at 40°C. The reaction was washed with water three times and dried with sodium sulfate. The product was obtained by distilling off the low boiling point fractions below 110°C at reduced pressure (0.3 mmHg), 61 g, (31% yield) of 3-benzyloxypropionaldehyde (10-D) were obtained. NMR (CDCl₃): 9.67 (t, 1H, CHO, J_{HH} = 0.033 Hz), 7.20 (s, 5 H, C₆H₅), 4.43 (s, 2 H, C₆H₅CH₂), 3.73 (t, 2 H, OCH₂, J_{HH} = 3 Hz), 2.60 (t of d, 2 H, CH₂CHO, J_{HH} = 3 Hz, J_{OH} = 1 Hz).

10

3-Benzyloxypropylidene diacetate (11-D) synthesis. 40 ml of acetic anhydride, 30 ml of ethyl ether and 3 ml of boron trifluoride/diethyl etherate were added to a 500 ml flask and 40 ml of 3-benzyloxypropionaldehyde was added to the flask in 5 minutes and stirred for another 10 minutes. The reaction mixture was washed with 200 ml of 10% sodium acetate and dried over sodium sulfate. The 3-benzyloxypropylidene (11-D) was crystallized on standing at -13°C and recrystallized with acetone and hexane as a colorless solid at 75% yield. NMR (CDCl₃): 7.67 (s, 5 H, C₆H₅), 6.90 (t, 1 H, CH(OAc)₂, J_{HH} = 3 Hz), 4.47 (s, 2 H, C₆H₅CH₂), 3.73 (t, 2 H, OCH₂, J_{HH} = 3 Hz), 1.90-2.23 (m, 2 H, CH₂CH), 2.00 (s, 6 H, CH₃). Anal. Calcd. for C₁₄H₁₈O₅: C, 63.14; H, 6.81. Found: C, 63.44; H, 6.77.

25

3-Hydroxypropylidene diacetate (12-D) synthesis. 1 ml of 3-benzyloxypropylidene diacetate (11-D), 10 ml of ethylacetate, 0.1 g of 5% palladium-on-charcoal and 1 drop of perchloric acid were hydrogenolized at a pressure of 44 lb/inch² for 15 minutes. 0.5 g of calcium carbonate was shaken with the reaction mixture which was later filtered and then the solvent evaporated. The product (12-D) was obtained as a colorless oil which was quantitatively crystallized on standing at -13°C. NMR (CDCl₃): 6.84 (t, 1 H, CH(OAc), J_{HH} = 3 Hz), 4.91 (s, 1 H, HO), 3.67 (t, 2 H, HOCH₂, J_{HH} = 3 Hz), 2.16-1.83 (m, 2 H, CH₂CH), 2.06 (m,

35

6 H, CH₃). anal. Calcd. for C₇H₁₂O₅. C, 47.72; H, 6.87.
Found: C, 48.69; H, 6.80.

O (3,3-Diacetatopropyl)-N,N-bis(2-chloroethyl)

5 phosphoramidic chloride (14-D) synthesis. A mixture of 2
ml of compound 12-D and 2 ml of triethylamine was added
dropwise to 1.32 ml of phosphorous oxychloride in 20 ml of
dichloromethane at -20°C, and the mixture was stirred for
20 minutes and then stirred at room temperature for 1 hour
10 and 40 minutes more. 2.516 g of bis(2-chloroethyl) amine
hydrochloride was added to the mixture, and then 4 ml of
triethylamine was added dropwise at -20°C and stirred for
20 minutes. The mixture was continuously stirred for 1
hour and 40 minutes at room temperature. The reaction
15 mixture was twice washed with water, once with phosphate
buffer (pH, 7.0) and twice with water, and then dried over
sodium sulfate. After removing the solvent, the product
(14-D) was purified by column chromatography
(ethylacetate : hexane - 1 : 1). 1.615 g of slightly
20 yellow oil product was obtained, 29%. NMR (CDCl₃): 6.83
(t, 1 H, CH(OAc), JHH = 3 Hz), 4.43-4.00 (q, 2 H, OCH₂,
JHH = 3 Hz, JOH = 2.98 Hz), 3.77 (m, 2 H, CH₂CH₂Cl),
2.37-1.97 (m, 2 H, CH₂CH), 2.07 (s, 6 H, CH₃).

25 O-(3,3-Diacetatopropyl)-N,N-bis(2-chloroethyl)

phosphorodiamide (15-D) synthesis. To 2.32 g of compound
14 was added 50 ml of 1 N ammonis in dichloromethane at -
20°C and the mixture was then stirred for 1 hour at room
temperature. After the solvent was removed by
30 evaporation, ether was added and the suspension was
filtered. Ether was removed, and the residue was submitted
to SiO₂ column chromatography and eluted with chloroform
and acetone (1 : 1) to give 1.57 g of product 15, (71%),
as a yellow oil which was crystallized on standing at -
35 13°C NMR (CDCl₃): 6.88 (t, 1 H, CH(OAc)₂, JHH = 3 Hz),
4.10 (q, 2 H, CH₂O, JHH = 3Hz, JHH = 3 Hz), 3.3-3.8 (m, 10

H, $\text{CH}_2\text{CH}_2\text{Cl}$ and NH), 2.0-2.3 (m, 2 H, $\text{CH}_2\text{CH}(\text{OAc})_2$), 2.10 (s, 6H, CH_3). Anal. Calcd. for $\text{C}_{11}\text{H}_{21}\text{Cl}_2\text{N}_2\text{O}_6\text{P}$: C, 34.84; H, 5.58; N, 7.39. Found: C, 34.66; H, 5.44; N, 7.12.

5 O (3,3-Diacetatopropyl)-N,N-bis(2-chloroethyl)-N¹-
 methylphosphorodiamide (16-D) synthesis. 3.5 ml of 3 N
monomethylamine in dichloromethane at -20°C was added to
2.12 g of compound 14-D and stirred for 1 hour at room
temperature. The other steps were the same as in making
10 compound 15-D. 0.41 g of product (16-D) was obtained
(20%) as a yellow oil. NMR (CDCl_3): 6.86 (t, 1 H,
 $\text{CH}(\text{OAc})_2$, JHH = 3), 4.23-3.96 (q, 2 H, OCH_2 , JHH = 3 Hz,
JOH = 3 Hz), 3.76-3.15 (m, 8 H, $\text{CH}_2\text{CH}_2\text{Cl}$), 2.78-2.43 (m, 4
H, CH_3NH), 2.18-1.95 (m, 2 H, $\text{CH}_2\text{CH}(\text{OAc})_2$), 2.08 (s, 6 H,
15 CH_3). Anal. Calcd. for $\text{C}_{12}\text{H}_{23}\text{Cl}_2\text{N}_2\text{O}_6\text{P}$: C, 36.65; H,
5.90; N, 7.13. Found: C, 36.59; H, 6.05; N, 7.30.

O (3,3-Diacetatopropyl)-N,N-bis(2-chloroethyl)-N¹-
 ethylphosphorodiamide (17-D) synthesis. To 2.055 g of
20 compound 14-D in 20 ml of dichloromethane, 0.66 ml of
ethylamine was added dropwise at -20°C, and the mixture
was stirred for 75 minutes at room temperature. The other
steps were the same as for making compound 15-D. 0.97 g
of product (17-D) was obtained (46%) as a yellow oil. NMR
25 (CDCl_3): 6.83 (t, 1 H, $\text{CH}(\text{OAc})_2$, JHH = 3 Hz), 4.19-3.86
(q, 2 H OCH_2 , JHH = 3 Hz, JHH = 3 Hz), 3.76-2.70 (m, 11 H,
 $\text{CH}_2\text{CH}_2\text{Cl}$ and CH_2NH), 2.26-1.93 (m, 2 H, $\text{CH}_2\text{CH}(\text{OAc})_2$), 2.10
(s, 6 H, CH_3), 1.26-0.98 (m, 3 H, $\text{CH}_3\text{CH}_2\text{NH}$). Anal. Calcd.
for $\text{C}_{13}\text{H}_{25}\text{Cl}_2\text{N}_2\text{O}_6\text{P}$: C, 38.34; H, 6.19; N, 6.88. Found:
30 C, 38.25; H, 6.20; N, 6.63.

O-(3,3-Diacetatopropyl)-N,N-bis(2-chloroethyl)-
 N¹,N¹-dimethylphosphorodiamide (18-D) synthesis. To a
mixture of 1.066 g of compound 14-D and 0.27 g of
35 dimethylamine hydrochloride, 0.45 ml of triethylamine was
added dropwise at -20°C. This was then stirred for 2

-28-

hours at room temperature. The other steps were the same as in making compound 15-D. 0.42 g of product was obtained as a yellow oil which was crystallized on standing at -13°C, 38%. NMR (CDCl₃): 6.80 (t, 1 H, CH(OAc)₂, JHH = 3 Hz), 4.19-3.86 (q, 2 H, OCH₂, JHH = 3 Hz, JOH = 3 Hz), 3.70-3.06 (m, 8 H, CH₂CH₂Cl), 2.73-2.56 (d, 6 H, (CH₃)₂N, JNH = 8 Hz), 2.26-1.96 (m, 2 H, CH₂CH(OAc)₂), 2.05 (s, 6 H, CH₃). Anal. Calcd. for C₁₃H₂₅Cl₂N₂O₆P: C, 38.34; H, 6.19; N, 6.88. Found C, 37.91; H, 5.92; N, 6.47.

O (3,3-Diacetatoethyl)-N,N-bis(2-chloroethyl)-N¹,N¹-diethylphosphorodiamide (19-D) synthesis. To 6.04 g of compound 14-D in 10 ml of dichloromethane, was added 0.31 ml of diethylamine dropwise at -20°C. The mixture was stirred for 3 hours at room temperature. The other steps were the same as in making compound 15-D. 0.239 g of product (19-D) was obtained as a yellow oil, 36%. NMR (CDCl₃): 6.86 (t, 1 H, CH(OAc)₂, JHH = 3 Hz), 4.20-3.86 (q, 2 H, OCH₂, JHH = 3 Hz, JOH = 3 Hz), 3.76-2.80 (m, 12 H, CH₂CH₂Cl and CH₃CH₂N, 2.29-1.98 (m, 2 H, CH₂CH(OAc)₂), 2.03 (s, 6 H, CH₃), 1.50 (t, 6 H, CH₃CH₂, JHH = 3). Anal. Calcd. for C₁₅H₂₉Cl₂N₂O₆P: C, 41.39; H, 6.72; N, 6.44. Found: C, 41.59; H, 6.62; N, 6.24.

EXAMPLE 2

FURTHER SYNTHESIS OF CYCLOPHOSPHAMIDE ANALOGS

Alterations of the reaction conditions shown in Example 1 were performed as follows to synthesize other analogs. See Figure 4.

For the compounds 20-E and 21-E, the reaction sequence was altered. One equivalent of compound 12-D and triethylamine were added to 3 equivalents of phosphorus

oxychloride. Instead of adding bis(2-chloroethyl)amine which would have produced compound (14-D), alcohol (ROH) (methanol or ethanol) and triethylamine were added to compound 13-D to produce compound 14-E. Then bis(2-chloroethyl)amine and triethylamine were added and compounds 20-E and 21-E were obtained by column chromatography (Figure 4).

O (3,3-Diacetatopropyl)-O-methyl-N,N-bis(2-chloroethyl) phosphoramidate (20-E) synthesis. To 0.33 ml of oxyphosphorous chloride in 10 ml of dichloromethane, a mixture of 0.5 ml of 12 and 0.5 ml of triethylamine at -20°C was added dropwise, and stirred for 20 minutes and then for another 100 minutes at room temperature. A mixture of 0.2 ml of methanol and 0.5 ml of triethylamine was then added at -20°C, and stirred for 20 minutes and then for another 100 minutes at room temperature. 0.5 g of bis(2-chloroethyl)amine hydrochloride and 1 ml of triethylamine were added, again at -20°C, and stirred for 2 hours at room temperature. The other steps were as described in making compound 15-D. 0.189 g of product (20-E) was obtained as a yellow oil, 14%. NMR (CDCl₃), 6.86 (t, 1 H, CH(OAc)₂, J_{HH} = 3 Hz), 4.37-3.30 (m, 13 H, OCH₂, CH₃O and CH₂CH₂Cl), 2.26-2.06 (m, 2 H, CH₂CH(OAc)₂, 2.03 (s, 6 H, CH₃). Anal. Calcd. for C₁₂H₂₂C₁₂N₂O₇P: C, 36.56; H, 5.63; N, 3.55. Found: C, 38.12; H, 5.92; N, 3.01.

O (3,3-Diacetatopropyl)-O-ethyl-N,N-bis(2-chloroethyl)phosphoramidate (21-E) synthesis. The steps and reagents were the same with synthesizing compound 20-E except 0.27 ml of ethanol instead of methanol was used. 0.692 g of product (21-E) was obtained as a yellow oil, 48%. NMR (CDCl₃): 6.84 (t, 1 H, CH(OAc)₂, J_{HH} = 3 Hz), 4.43-3.26 (m, 13 H, OCH₂, CH₃CH₂ and CH₂CH₂Cl), 2.23-2.03 (m, 2 H, CH₂CH(OAc)₂), 2.06 (s, 6 H, CH₃) 1.36 (t, 3

H, CH_3CH_2 , $\text{JHH} = 3 \text{ Hz}$). Anal. Calcd. for $\text{C}_{13}\text{H}_{24}\text{Cl}_2\text{N}_2\text{O}_7\text{P}$: C, 38.25; H, 5.93; N, 3.43. Found: C, 38.01; H, 6.10; N, 3.16.

5

EXAMPLE 3

FURTHER CYCLOPHOSPHAMIDE ANALOG SYNTHESIS

The modification as illustrated in Figure 5 was used
10 to produce compound 22-F.

O-(3,3-Diacetatopropyl)-N-(2-chloroethyl)-N-(2-chloroethyl)phosphorodiamide (22-F) synthesis. To 0.66 ml of oxyphosphorous chloride in 20 ml of dichloromethane was
15 added a mixture of 1 ml of compound 12-D and 1 ml of triethylamine at -20°C dropwise and stirred for 20 minutes, and the mixture was then stirred for another 100 minutes at room temperature. The other steps were as described in making compound 15-D (see Figure 5). 0.32 g
20 of product (22-F) was obtained as a yellow oil, 12% yield. NMR (CDCl_3): 6.89 (t, 1 H, $\text{CH}(\text{OAc})_2$, $\text{JHH} = 3 \text{ Hz}$), 4.20-3.90 (q, 2 H, CH_2 , $\text{JHH} = 3 \text{ Hz}$, $\text{JOH} = 3 \text{ Hz}$), 3.67-3.03 (m, 10 H, NH, NH and $\text{CH}_2\text{CH}_2\text{Cl}$), 2.26-2.00 (m, 2 H, $\text{CH}_2\text{CH}(\text{OAc})_2$). 2.06 (s, 6 H, CH_3). Anal. Calcd. for
25 $\text{C}_{11}\text{H}_{21}\text{Cl}_2\text{N}_2\text{O}_6\text{P}$: C, 34.84; H, 5.58; N, 7.37. Found C, 35.30; H, 5.88; N, 6.57.

Cyclohexylammonium Hydrogen N,N-di-(2-chloroethyl)phosphorodiamidate synthesis. 25 g of bis(2-
30 chloroethyl)amine hydrochloride in 65 ml of oxyphosphorus chloride was heated to reflux for 12 hours. The excess oxyphosphorus was removed by evaporation. Di(2-chloroethyl)phosphoramidic dichloride was crystallized from petroleum ether and acetone (1 : 1). It was
35 recrystallized 3 times with the same solvent. 14.5 g of white crystals were obtained, m.p. $54-56^\circ\text{C}$. This melting

-31-

point was the same as that previously reported. 3 g of di(2-chloroethyl)phosphoramidic dichloride and 1.15 g of phenol were added to 20 ml of toluene and heated to reflux, 1.85 ml of triethylamine was then added over 2 minutes, the reflux continued for 4 hours and then left overnight. The suspension was filtered and the filtrate was submitted to SiO₂ column chromatography (hexane : ethylacetate = 7:3). Phenyl-di(2-chloroethyl)phosphoramidic chloride was obtained as a yellow oil, 3.361 g, 92% NMR (CDCl₃): 7.3 (s, 5 H, C₆H₅), 3.87-3.33 (m, 8 H, CH₂CH₂Cl). 2.115 g of Phenyl-di(2-chloroethyl) phosphoramidic chloride in toluene was bubbled with ammonia for 30 minutes. The precipitate was filtered and the solvent was removed by evaporation. The residue was diluted to cloudiness with petroleum ether and left overnight. Phenyl N,N-di(2-chloroethyl)phosphorodiamidate was crystallized, filtered, and without further purification, it was added to 50 ml of 100% ethanol and 0.4 g of platinum(IV) oxide and hydrogenolized for 15 minutes under the pressure 11 lb/inch². The mixture was filtered and 0.5 ml of cyclohexamine was added immediately. After the evaporation, the residue was washed onto a filter with ether. 0.501 g cyclohexylammonium hydrogen N,N-di(2-chloroethyl)phosphorodiamidate as an off-white powder was obtained, 23%, m.p. 124-126°C.

EXAMPLE 4

ADDITIONAL CYCLOPHOSPHAMIDE ANALOG SYNTHESIS

30

Compounds B-8 to B-53 described in Table 1 were prepared by reaction of a precursor phosphoramido-chloridate (compare Figure 3, 14-D) or phosphorochloridate (compare Figure 4 or Figure 5) with the appropriate amine or alcohol by the methods described in Examples 1-3. Thus, compounds B-18 to B-25 and B-39 to B-53 were

prepared by the methods described previously for compounds B-1 to B-7. The oxygen analogs B-26 to B-31 were prepared by the general procedure described for compounds B-8 and B-9. The phosphonate analogues B-33 to B-38 were prepared by the general method described below in Example 5.

EXAMPLE 5

Synthesis of:)-(3,3-Diacetoxypropyl)-N,N-bis(2-chloroethyl)methylphosphonamidochloridate (B-10). A solution of 3-hydroxypropionaldehyde diacetoxy acetal (12-D) (0.5 g, 2.8 mmoles) in CH_2Cl_2 (5 mL) was added simultaneously with a solution of Et_3N (0.4 ml, 2.8 mmoles) in CH_2Cl_2 (3 mL), over a period of 30 min, to a stirred solution of methylphosphonic dichloride (378 mg, 2.8 mmoles) in CH_2Cl_2 (5 mL) maintained at -30°C in a dry-ice/acetone cooling bath. After 30 min. the reaction mixture was warmed to room temperature and stirred for 2 h. It was then cooled again to -30°C and N,N-bis(2-chloroethyl)amine hydrochloride (0.5 g, 2.8 mmoles) was added followed by Et_3N (0.8 ml, 5.6 mmoles). After 30 min the reaction warmed to room temperature and stirred for a further 2 h. It was then washed with 0.45 M potassium phosphate buffer, pH 7.0 (20 mL) and H_2O (20 mL x 2). The organic phase was dried over anhydrous Na_2SO_4 . The solvent was evaporated and the remaining residue was submitted to flash chromatography on a column of silica using EtOAc-hexane (1:1, v/v) as eluent. Fractions (5 mL each) containing pure B-10 as evidenced by TLC analyses where combined and evaporated to give a viscous, pale yellow oil. It was dried in vacuo at 0.01 mm Hg over P_2O_5 for 48 h. Yield 456 mg (40%). ^1H NMR (CDCl_3): 6.92 (t, 1 H, $\text{CH}(\text{OAc})_2$), 3.90-4.32 (m, 2 H POCH_2), 3.60-3.67 (t, 4 H, 2 x CH_2Cl), 3.34-3.40 (m, 4 H, 2 x NCH_2), 2.02-2.10 (m, 2 H, $\text{CHCH}_2\text{CH}_2\text{O}$), 2.05 (s, 6 H, 2 x OCOCH_3), 1.28 (d, J= 16 Hz, 3 H, CH_3).

EXAMPLE 6
IN VITRO CYTOTOXICITY OF COMPOUNDS
 SYNTHESIZED IN EXAMPLES 1-3

5

Certain of the above referenced compounds were tested against L1210 lymphatic leukemia cells in vitro, the results being shown in Table 2. Cyclophosphamide (CF), ASTA Z 7557 and phosphoramidate mustard (PM) were used as positive controls. The toxicity of compounds 16-D to 19-D to L1210 cells were about the same. This suggested that the cyclic intermediate structure may not be essential for the antitumor selectivity because compounds 16-D and 17-D can cyclize, at least theoretically, but 18-D and 19-D cannot, due to their chemical structure. That compounds 15-D to 19-D and 22 were more effective than compounds 20-E and 21-E suggested that a N at the R position was important for antitumor activity. All of the 8 compounds were at least as toxic as ASTA Z 7557 and more toxic than phosphoroamide mustard, indicating that the aldehyde intermediate may be important for the antitumor selectivity. Compounds 15-D and 22-F, the precursor of the two clinically important antitumor drugs, cyclophosphamide and isophosphamide, respectively were much more toxic than ASTA Z 7557.

TABLE 2

30	Compound											
	No.	15-D	16-D	17-D	18-D	19-D	20-E	21-E	22-F	CP	ASTA	PM
	ED ₅₀	0.6	5.8	6.4	7.1	7.8	13.0	13.6	1.7	>20	13.0	18.0
	(microgram/ml)											

35

-34-

ED₅₀ was the concentration of drug that kills 50% of the cells. The compounds were incubated with L1210 lymphotic leukemia cells for 72 hr at 37°C with the compound over the concentration range 0.5-20 microgram/ml. The
5 viability of the cells was determined by a spectrophotometric assay.

Drugs were dissolved in sterile water and filtered through a 0.22 um (micrometer) filter (Millipore
10 Corporation). The stock drug solutions were 1 mg/ml. 2.5×10^{-6} L1210 leukemia cells in 150 ul (microliter) RPMI 1640 medium complemented with 10% fetal calf serum were placed into every well of a 96 well plate. Drugs in 15 ul solution were then added and the cells were incubated for
15 72 hours at 37°C. 5×10^{-4} mg of MTT in 15 ul solution was added to each well and then incubated for 4 hours at 37°C. Acid-isopropanol (180 ul of 0.04 N HCl in isopropanol) was added to each well to dissolve the crystallized dye produced. The plates were read on a
20 multiwell scanning spectrophotometer (ELISA reader) at a wavelength of 570 nm. The ED50 values were calculated.

EXAMPLE 7

25 ACETALDOPHOSPHAMIDE: A PROMISING NEW ALTERNATIVE TO 4-HYDROPEROXYCYCLOPHOSPHAMIDE FOR THE IN VITRO ELIMINATION OF LEUKEMIC CELLS FROM HUMAN BONE MARRROW

In vitro active cyclophosphamide derivatives such as
30 4-hydroperoxycyclophosphamide (4-HC) have been widely investigated for their potential to eliminate malignant cells from bone marrow prior to hematopoietic rescue following intensive chemotherapy. Studies of the present invention suggest that 4-HC is more active against human
35 (myelogenous) leukemia cells than against normal granulocyte-macrophage progenitors (GM-CFC). Using long-

term human marrow cultures, a sparing effect of 4-HC on GM-CFC ancestor cells was also observed. These differential drug sensitivities may be due to different intracellular levels of aldehyde dehydrogenase, a key enzyme in the deactivation of aldophosphamide (ALD); the latter is an important intermediate in the conversion of 4-HC to the presumed ultimate active metabolite, phosphorodiamidic mustard. In a search for new stable precursors to an acetalaldophosphamide (compound B-1, Table 1) was developed. The cytotoxic effects of compound B-1 on human normal GM-CFC and leukemia colony forming cells (L-CFC) were determined in vitro using both prolonged (8 days) and short-term (0.5-4.0 hr) drug exposures (see Table 3). Compound B-1 was approximately 10-fold more cytotoxic than 4-HC on a molar basis. The IC_{50} values (the drug concentrations required to reduce colony formation to 50% of controls) of compound B-1 for normal human GM-CFC were approximately 2-fold greater than those for the human myeloid cell line KBM-3 when assessed by continuous exposure. Interestingly, the IC_{50} values for the GM-CFC after 1 hr drug exposure were 10-fold greater than those for the L-CFC. Thus, compound B-1 is more cytotoxic to KBM-3 leukemic clonogenic cells than to normal GM-CFC cells and the differential appears most pronounced after short-term exposure to relatively high drug concentrations.

TABLE 3

5	<u>Cell type</u>	<u>IC₅₀ (ng/mL; range)</u>	
		<u>1 hr exposure</u>	<u>8 days exposure</u>
	Normal, GM-CFC	1,000-1,500	45-55
	KBM-3, L-CFC	100-200	20-25
10	Ratio GM-CFC/L-CFC	10	2

Experiments further delineating the differential
15 cytotoxicities of compound B-1 in comparison to 4-HC and
in combination with other drugs are in progress are
further confirming that compound B-1 is a promising new
agent for the in vitro elimination of leukemic cells from
bone marrow prior to autologous transplantation.

20


EXAMPLE 8

CYTOTOXIC GLYCOSIDE DERIVATIVES

The cytotoxic glycoside antibiotics doxorubicin and
25 daunomycin have the structures shown in Figure 6. A
number of bis(acyloxypropyl)phosphoramidates of the
following general structure (C), where the R¹ group is
doxorubicin or daunomycin bonded to the phosphorus through
the sugar amino group, have been prepared.

30

-37-



5

C

Table 4 shows the R, R¹ and R² substituents in
 10 structure C to produce compound No. C-1 to C-8.

TABLE 4

Compound No.		R	R ¹	R ²
15	C-1	CH ₃	N-(3')-Doxorubicin	N(CH ₂ CH ₂ Cl) ₂
	C-2	CH ₃	N-(3')-Daunomycin	N(CH ₂ CH ₂ Cl) ₂
	C-3	CH ₃	N-(3')-Doxorubicin	NHCH ₂ CH ₂ Cl
	C-4	CH ₃	N-(3')-Daunomycin	NHCH ₂ CH ₂ Cl
20	C-5	C(CH ₃) ₃	N-(3')-Doxorubicin	N(CH ₂ CH ₂ Cl) ₂
	C-6	C(CH ₃) ₃	N-(3')-Daunomycin	N(CH ₂ CH ₂ Cl) ₂
	C-7	C(CH ₃) ₃	N-(3')-Doxorubicin	NHCH ₂ CH ₂ Cl
	C-8	C(CH ₃) ₃	N-(3')-Daunomycin	NHCH ₂ CH ₂ Cl

25 The preparation method for these compounds is described with respect to the prototype, N-[0-(3,3-diacetoxypropyl)-N,N-bis(2-chloroethyl)phosphorodiamido]-doxorubicin (C-1).

30 N,N-Diisopropylamine (0.032 mL, 0.2 mmoles) was added, with stirring, to a solution of doxorubicin free base (100 mg, 0.18 mmoles) in anhydrous chloroform/methanol (20:1) (15 ml). The mixture was cooled to -40°C and 0-(3,3-diacetoxypropyl)-N,N-bis(2-chloroethyl)phosphoramidochloridate (90 mg, 0.2 mmoles) in
 35 anhydrous dichloromethane (2 ml) was added. The reaction

mixture was stirred for 30 min at -40°C, then at room temperature for 16 h. The solution was washed sequentially with an equal volume of 0.05 M phosphate buffer (pH 7) and water, and dried over MgSO_4 . The solvent was evaporated and the residue was chromatographed on a column of silica using $\text{CHCl}_3/\text{MeOH}$ (20:1 to 5:1) as eluent. The product was isolated as a red solid. Yield 23 mg (14%). NMR ($\text{CDCl}_3/\text{CD}_3\text{OD}$) 13.91 (s, 1 H, OH), 13.18 (s, 1 H, OH), 7.94 (d, $J = 5$ Hz, H-3), 7.72 (m, 1 H, H-2), 7.38 (d, $J = 5$ Hz, H-1), 6.93 (t, 1 H, $\text{CH}(\text{OAc})_2$), 5.20 (d, $J = 18$ Hz, NHP), 4.7 (s, 2 H, CH_2OH), 4.01 (s, 3 H, OCH_3), 3.2-3.70 (m, 8H, 2 x $\text{CH}_2\text{CH}_2\text{Cl}$), 2.01 (s, 6H, 2 x Ac), 1.06 (d, $J = 4$ Hz, 3H, CH_3).

The anticipated mechanism of activation of these compounds is shown in Figure 7. As shown in Scheme 1, compound C is hydrolyzed to the aldehyde C-I by tissue carboxylate esterases. In normal cells, C-I is then oxidized by aldehyde dehydrogenase to the carboxylic acid, C-II, a chemically unreactive compound. However, in tumor cells, which are comparatively deficient in aldehyde dehydrogenase, C-I undergoes an E-2 elimination reaction to give C-III. The latter compound, like phosphorodiamidic mustard, should be chemically reactive and form covalent adducts with target DNA.

Such differential metabolism should not only lead to higher levels of the cytotoxic moiety C-III in tumor cells compared to normal cells, but might overcome resistance to the parent anthracyclines (doxorubicin, daunomycin, etc.) arising from efficient cellular drug efflux (the multidrug resistance phenotype).

Growth inhibition of cultured L1210 leukemia cells was used as a measure of the relative cytotoxicities of the anthracycline derivatives of the present invention.

- 5 L1210 murine leukemia cells were maintained in vitro by serial culture in RPMI Medium 1640 containing 10% heat-inactivated fetal calf serum, L-glutamine (2 micro-M/ml), 2-mercaptoethanol (10 micro-M), penicillin (50 U/ml), streptomycin 50 micro-g/ml) at 37°C in a humidified
10 atmosphere of 5% CO₂ and 95% air. Cells in exponential growth at a density of 10⁶ cells/ml were exposed to varying drug concentrations for 1 h at 37°C. They were then harvested by centrifugation for 5 min at 1500 RPM, washed twice with ice-cold phosphate-buffered saline (2
15 ml), resuspended in drug-free medium at a concentration of 2 x 10⁵/ml, and cultured for 72 h. Cell viability was determined by the MTT assay. (Mossman, T (1983). Rapid colorimetric assay for cellular growth and survival application to proliferation and cytotoxicity assays. J.
20 Immunol. Meth. 65:55-63). The concentrations of drug inhibiting cell growth 50% (IC₅₀) is shown in Table 5.

TABLE 5
GROWTH INHIBITION OF L1210 LEUKEMIA CELLS IN VITRO
BY DOSORUBICIN AND DAUNOMYCIN ANALOGUES^a

5	-----		
	Compound	IC ₅₀ ^b , (micromolar)	
	C-1)	0.016	
	C-2)	0.018	
	C-3)	0.021	
10	C-4)	0.025	
	C-5)	0.017	
	C-6)	0.020	
	C-7)	0.035	
15	C-8)	0.030	

a Exponentially growing cells were exposed to varying drug concentrations for 96 h at 37°C. The cells were then centrifuged, resuspended, and cultured in drug-free medium for 72 h.

b The drug concentration that inhibited cell growth by 50% compared to untreated control cultures.


25

EXAMPLE 9

NUCLEOSIDE DERIVATIVES

Nucleoside analogues of the following general structure (D) were prepared as potential antitumor and anti-AIDS agents.

35



D

Table 6 shows the R, R¹ and R² substituents of structure D for compounds D-1 to D-4.

TABLE 6
NUCLEOSIDE DERIVATIVES SYNTHESIZED

5	<u>Compound</u>	<u>R</u>	<u>R¹</u>	<u>R²</u>
	<u>No.</u>			
	D-1	CH ₃	NH ₂	2',3'-dideoxyuridine-5'-yl
	D-2	C(CH ₃) ₃	NH ₂	2',3'-dideoxyuridine-5'-yl
	D-3	CH ₃	NH ₂	5-methyl-2',3'-dideoxyuridine-5'-yl
10	D-4	C(CH ₃) ₃	NH ₂	5-methyl-2',3'-dideoxyuridine-5'-yl

The method of synthesis of these compounds can be illustrated with respect to the 2',3' dideoxyuridine derivative (D-1).

15 A solution of 1,2,4-triazole (132.23 mg, 1.92 mmole) and POCl₃ (98 mg, 60 ul, 0.639 mmoles) was dissolved in dioxane (2 mL) [dried over 4 Angstrom molecular sieves (300°C/1 h)] and a solution of triethylamine (267 uL, 1.92

20 mmole) in dioxane (1 mL) was added dropwise during a 45 min period. After stirring for an additional 40 min, the reaction mixture was filtered under nitrogen into a flask containing dideoxyuridine (90.4 mg; 0.426 mmoles) which has previously been evaporated with pyridine. After 30

25 min, a solution of 3-hydroxypropionaldehyde diacetoxyl acetal (97.5 mg, 0.55 mmole) in dioxane (0.5 mL) was added. After stirring at room temperature for 5 hr the reaction mixture was concentrated to 1/3 of the starting volume and 1.3 mL of a 1.6 N solution of ammonia (2.13

30 mmole) in dioxane was added. After 30 min the reaction mixture was evaporated to dryness and the residue was taken up in the minimum volume of methanol and chromatographed on two thick layer (2 mm) plates (20 x 20) of silica. The product was isolated as a viscous

35 colorless oil. Its NMR spectra was consistent with the assigned structure.

The effectiveness against growth of L1210 cells of these nucleoside analogs was tested and the growth inhibition shown in Table 7.

5

TABLE 7

GROWTH INHIBITION OF L1210 LEUKEMIA CELLS
IN VITRO BY NUCLEOSIDE ANALOGUES^a

10	Compound	IC ₅₀ ^b , micro-M
15	D-1)	1.4
	D-2)	0.7
	D-3)	1.3
	D-4)	1.6

a Exponentially growing cells were exposed to varying drug concentrations for 96 h at 37°C. The cells were then centrifuged, resuspended, and cultured in drug-free medium for 72 h.

b The drug concentration that inhibited cell growth by 50% compared to untreated control cultures.

25

EXAMPLE 10

PREDICTED MECHANISM OF ACTIVATION

The anticipated mechanism of activation of these compounds is shown in Figure 8. Scheme 2 shows that compound G (where R₁ is a cytotoxic moiety) is converted to the aldehyde G-I by tissue esterases. In normal cells, G-I is preferentially converted to the carboxylic acid, G-II, by aldehyde dehydrogenase. G-II should be chemically stable and biologically inert. In tumor cells, however, G-I should undergo E-2 elimination to give the phosphorodiamidate, G-III. This compound will then be converted to the corresponding phosphate, G-IV, by spontaneous chemical or enzymatic hydrolysis. Such differential metabolism should lead to higher levels of

the R¹ cytotoxin such as a cytotoxic mustard, adriamycin or nucleotide analogue, G-IV, in tumor cells.


X X X X X X X

5

Changes may be made in the construction, operation and arrangement of the various compounds and procedures described herein without departing from the concept and scope of the invention as defined in the following claims.

CLAIMS:

1. A compound having the structure



10

wherein:


R is alkyl, aryl, or alkaryl;

15 X is N, NH, NHNH, NHO, ONH, or alkyl;

R^1 is hydrogen, alkyl, dialkyl, aryl, chloroalkyl, nitro, amine, benzyloxycarbonyl or t-butoxycarbonyl; and

20 R^2 is chloroethylamine or bis(chloroethyl)amine.

2. A compound having the structure:



30

wherein:

R is CH_3 , C_2H_5 , C_3H_7 , t- C_4H_9 or C_6H_5 ;

35 R^1 is NH_2 , NHCH_3 , NHC_2H_5 , NHC_3H_7 , NHC_4H_9 , $\text{NHCH}_2\text{CH}_2\text{Cl}$, NHC_6H_5 , $\text{N}(\text{CH}_3)_2$, $\text{N}(\text{C}_2\text{H}_5)_2$, $\text{N}(\text{C}_3\text{H}_7)_2$, $\text{NCH}_3(\text{C}_2\text{H}_5)$,

$\text{NCH}_3(\text{C}_3\text{H}_7)$, $\text{N}(\text{CH}_2\text{CH}_2\text{Cl})_2$, NHOH , $\text{NHNHCO}_2\text{CH}_2\text{C}_6\text{H}_5$,
 $\text{NHNHCO}_2\text{C}(\text{CH}_3)_3$, OCH_3 , OC_2H_5 , OC_3H_7 , OC_4H_9 , OC_6H_5 ,
 $\text{OC}_2\text{C}_6\text{H}_5$, CH_3 , C_2H_5 , C_3H_7 , C_4H_9 , CH_2NO_2 or CH_2NH_2 ; and

5 R^2 is $\text{NHCH}_2\text{CH}_2\text{Cl}$ or $\text{N}(\text{CH}_2\text{CH}_2\text{Cl})_2$.

3. A method of treating bone marrow to eliminate occult
 leukemic clonogenic cells comprising:

10

preparing at least one compound of claim 1 or 2; and

contacting bone marrow with a solution comprising of
 one or more of said compounds.

15

4. A method of eliminating tumor cells from a host or an
 organ of a host comprising:

20


preparing at least one compound of claim 1 or 2; and

treating a host or organ of a host with a solution
 comprising one or more of said compounds.

25

5. A stable aldophosphamide analog activatable by the
 action of an esterase and a subsequent spontaneous E-2
 elimination reaction to form acrolein and a phosphoramidic
 mustard, said phosphoramidic mustard having the formula

30




35

wherein:

R is NH_2 , NHCH_3 , NHC_2H_5 , NHC_3H_7 , NHC_4H_9 , $\text{NHCH}_2\text{CH}_2\text{Cl}$,
 NHC_6H_5 , $\text{N}(\text{CH}_3)_2$, $\text{N}(\text{C}_2\text{H}_5)_2$, $\text{N}(\text{C}_3\text{H}_7)_2$, $\text{NCH}_3(\text{C}_2\text{H}_5)$,
 5 $\text{NCH}_3(\text{C}_3\text{H}_7)$, $\text{N}(\text{CH}_2\text{CH}_2\text{Cl})_2$, NHOH , $\text{NHNHCO}_2\text{CH}_2\text{C}_6\text{H}_5$,
 $\text{NHNHCO}_2\text{C}(\text{CH}_3)_3$, OCH_3 , OC_2H_5 , OC_3H_7 , OC_4H_9 , OC_6H_5 ,
 $\text{OC}_2\text{C}_6\text{H}_5$, CH_3 , C_2H_5 , C_3H_7 , C_4H_9 , CH_2NO_2 or CH_2NH_2 ; and

10 R^1 is $\text{NHCH}_2\text{CH}_2\text{Cl}$ or $\text{N}(\text{CH}_2\text{CH}_2\text{Cl})_2$.

6. A compound having the structure:




20 wherein:

R is CH_3 , C_2H_5 , C_3H_7 , $\text{C}(\text{CH}_3)_2$ or C_6H_5 ;

25 R^1 is NH_2 , NHCH_3 , NHCH_2CH_3 , $\text{NHCH}_2\text{CH}_2\text{Cl}$, $\text{N}(\text{CH}_3)_2$,
 $\text{N}(\text{CH}_2\text{CH}_3)_2$, $\text{N}(\text{CH}_2\text{CH}_2\text{Cl})_2$, $\text{NHCH}_2\text{CH}_2\text{CH}_2\text{CH}_3$, $\text{NCH}_3(\text{C}_2\text{H}_5)$,
 $\text{NCH}_3(\text{C}_3\text{H}_7)$, NHC_6H_5 , NHOH , $\text{NHNHCO}_2\text{CH}_2\text{C}_6\text{H}_5$,
 $\text{NHNHCO}_2\text{C}(\text{CH}_3)_3$, OCH_3 , OCH_2CH_3 , OC_3H_7 , OC_4H_9 , OC_6H_5 ,
 $\text{OCH}_2\text{C}_6\text{H}_5$, $\text{ONHCO}_2\text{C}(\text{CH}_3)_3$, $\text{OCH}_2\text{CH}_2\text{CH}(\text{OAc})_2$,
 $\text{OP}(\text{O})\text{N}(\text{CH}_2\text{CH}_2\text{Cl})_2$, CH_3 , CH_2CH_3 , $\text{CH}_2\text{CH}_2\text{CH}_3$,
 30 $\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$, CH_2NO_2 , or CH_2NH_2 ; and

R^2 is $\text{N}(\text{CH}_2\text{CH}_2\text{Cl})_2$ or $\text{NHCH}_2\text{CH}_2\text{Cl}$.

7. A compound having the structure:



wherein:

10


R is CH₃, C₂H₅, C₃H₇, C(CH₃)₂ or C₆H₅;

R¹ is a cytotoxic glycoside; and

15 R² is N(CH₂CH₂Cl)₂ or NHCH₂CH₂Cl.

8. A compound having the structure:

20



25


wherein:

R is CH₃, C₂H₅, C₃H₇, C(CH₃)₂ or C₆H₅;

30 R¹ is N-(3')-Doxorubicin or N-(3')-Daunorubicin; and

R² is N(CH₂CH₂Cl)₂ or NHCH₂CH₂Cl.

10. A compound having the structure:



wherein:


10

R is CH_3 , C_2H_5 , C_3H_7 , $\text{C}(\text{CH}_3)_2$ or C_6H_5 ;

R^1 is NH_2 ; and

15 R^2 is a nucleoside.

11. A compound having the structure:



25

wherein:

R is CH_3 , C_2H_5 , C_3H_7 , $\text{C}(\text{CH}_3)_2$ or C_6H_5 ;


30 R^1 is NH_2 ; and

R^2 is 2',3'-dideoxyuridine-5'yl or 5-methyl-2',3'-dideoxyuridine.

35

12. A compound having the structure

5



10


wherein:

Y is P or S;

15 X is O, S or NZ, where Z is H or alkyl; and

one or both of R and R¹ is (are) (a)cytotoxin(s), when only one is, the other being H, CH₂Z, NZ₂, OZ or SZ, where Z is H or alkyl.


1 / 7

Fig. 1

SUBSTITUTE SHEET

2 / 7 .


Fig. 2



SUBSTITUTE SHEET

3 / 7



Fig. 3



15-D: $X = NH_3$ AND $R = NH_2$, 16-D: $X = HCl, NH_2CH_3$ AND $R = NHCH_3$,
17-D: $X = HCl, NH_2CH_2CH_3$ AND $R = NHCH_2CH_3$, 18-D: $X = HCl, N(CH_3)_2$,
AND $R = N(CH_3)_2$, 19-D: $X = NH(CH_2CH_3)_2$ AND $R = N(CH_2CH_3)_2$


SUBSTITUTE SHEET

4 / 7

Fig. 4*Fig. 5*

SUBSTITUTE SHEET

517



WITH DOXORUBICIN, X - OH

WITH DAUNOMYCIN, X - H

Fig. 6

SUBSTITUTE SHEET

6/7

NOT TAKEN INTO CONSIDERATION
FOR THE PURPOSES
OF INTERNATIONAL PROCESSING

7/7

NOT TAKEN INTO CONSIDERATION
FOR THE PURPOSES
OF INTERNATIONAL PROCESSING

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 89/01214

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) *

According to International Patent Classification (IPC) or to both National Classification and IPC

IPC⁵: C 07 F 9/24, A 61 K 35/28, C 07 F 9/44

II. FIELDS SEARCHED

Minimum Documentation Searched ?

Classification System

Classification Symbols

IPC⁵

C 07 F 9/00, C 07 H 15/00

Documentation Searched other than Minimum Documentation
to the extent that such Documents are included in the Fields Searched *

III. DOCUMENTS CONSIDERED TO BE RELEVANT *

Category *	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
X	Cancer Research, volume 48, 15 January 1988, M. Beran et al.: "The effects of acetaldophosphamide, a novel stable aldophosphamide analogue, on normal human and leukemic progenitor cells in Vitro: implications for use in bone marrow purging", pages 339-345 see page 340, compound 1	1
A	EP, A, 0098601 (MAX-PLANCK-GESELLSCHAFT) 18 January 1984 see claims	1
A	FR, A, 2429795 (RHONE POULENC) 25 January 1980 see claim 1	7,8,10,11
A	Journal of the American Chemical Society, volume 95, no. 3, 7 February 1973, A. Takamizawa et al.: "Studies on cyclophosphamide metabolites and their related compounds. II. Preparation of an active species ./.	1,2,6

* Special categories of cited documents: ¹⁰

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"Z" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search

Date of Mailing of this International Search Report

2nd November 1989

18. 12. 89

International Searching Authority

Signature of Authorized Official

EUROPEAN PATENT OFFICE

T.K. WILLIS

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

E, L	of cyclophosphamide and some related compounds", pages 985-986 see the whole article -- US, A, 4841085 (D. FARQUHAR) 20 June 1989 see the whole document -----	1,2,5,6
------	--	---------

V. ☒ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☒ Claim numbers XX because they relate to subject matter not required to be searched by this Authority, namely:
xx claims 3, 8, 4
pls. see Rule 39.1 (iv) - PCT:
Methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods.

2. ☐ Claim numbers because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claim numbers because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. ☐ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING

This International Searching Authority found multiple inventions in this international application as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.
2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:
3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:
4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

- ☐ The additional search fees were accompanied by applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.**

US 8901214

SA 28097

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.
The members are as contained in the European Patent Office EDP file on 08/12/89
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A- 0098601	18-01-84	DE-A- 3225227	12-01-84
		DE-A- 3374866	21-01-88
		WO-A- 8400368	02-02-84
		EP-A,B 0112871	11-07-84
		US-A- 4739095	19-04-88
FR-A- 2429795	25-01-80	None	
US-A- 4841085	20-06-89	None	